These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 7869472)
21. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas. Goto K; Konomoto T; Hayashi K; Kinukawa N; Naito S; Kumazawa J; Tsuneyoshi M Mod Pathol; 1997 May; 10(5):428-37. PubMed ID: 9160306 [TBL] [Abstract][Full Text] [Related]
22. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Wallerand H; Bakkar AA; de Medina SG; Pairon JC; Yang YC; Vordos D; Bittard H; Fauconnet S; Kouyoumdjian JC; Jaurand MC; Zhang ZF; Radvanyi F; Thiery JP; Chopin DK Carcinogenesis; 2005 Jan; 26(1):177-84. PubMed ID: 15347601 [TBL] [Abstract][Full Text] [Related]
23. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Hartmann A; Schlake G; Zaak D; Hungerhuber E; Hofstetter A; Hofstaedter F; Knuechel R Cancer Res; 2002 Feb; 62(3):809-18. PubMed ID: 11830537 [TBL] [Abstract][Full Text] [Related]
24. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Thorlacius S; Börresen AL; Eyfjörd JE Cancer Res; 1993 Apr; 53(7):1637-41. PubMed ID: 8453635 [TBL] [Abstract][Full Text] [Related]
25. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332 [TBL] [Abstract][Full Text] [Related]
26. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma. Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850 [TBL] [Abstract][Full Text] [Related]
27. p53 mutations in bladder carcinoma cell lines. Cooper MJ; Haluschak JJ; Johnson D; Schwartz S; Morrison LJ; Lippa M; Hatzivassiliou G; Tan J Oncol Res; 1994; 6(12):569-79. PubMed ID: 7787250 [TBL] [Abstract][Full Text] [Related]
28. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152 [TBL] [Abstract][Full Text] [Related]
29. Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas. Yamaguchi T; Toguchida J; Wadayama B; Kanoe H; Nakayama T; Ishizaki K; Ikenaga M; Kotoura Y; Sasaki MS Anticancer Res; 1996; 16(4A):2009-15. PubMed ID: 8712735 [TBL] [Abstract][Full Text] [Related]
30. Microsatellite alterations at chromosomes 9p, 13q, and 17p in nonmuscle-invasive transitional cell carcinomas of the urinary bladder. Erbersdobler A; Friedrich MG; Schwaibold H; Henke RP; Huland H Oncol Res; 1998; 10(8):415-20. PubMed ID: 10100758 [TBL] [Abstract][Full Text] [Related]
31. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410 [TBL] [Abstract][Full Text] [Related]
32. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status. Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509 [TBL] [Abstract][Full Text] [Related]
33. Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer. Hirao S; Hirao T; Marsit CJ; Hirao Y; Schned A; Devi-Ashok T; Nelson HH; Andrew A; Karagas MR; Kelsey KT Cancer; 2005 Nov; 104(9):1918-23. PubMed ID: 16149093 [TBL] [Abstract][Full Text] [Related]
34. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion]. Słojewski M Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306 [TBL] [Abstract][Full Text] [Related]
35. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder. Dekairelle AF; Tombal B; Cosyns JP; Gala JL Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567 [TBL] [Abstract][Full Text] [Related]
36. Chromosome 8 numerical aberration and C-MYC copy number gain in bladder cancer are linked to stage and grade. Mahdy E; Pan Y; Wang N; Malmström PU; Ekman P; Bergerheim U Anticancer Res; 2001; 21(5):3167-73. PubMed ID: 11848469 [TBL] [Abstract][Full Text] [Related]
37. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632 [TBL] [Abstract][Full Text] [Related]
38. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Olumi AF; Tsai YC; Nichols PW; Skinner DG; Cain DR; Bender LI; Jones PA Cancer Res; 1990 Nov; 50(21):7081-3. PubMed ID: 2208176 [TBL] [Abstract][Full Text] [Related]
39. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses. Denzinger S; Mohren K; Knuechel R; Wild PJ; Burger M; Wieland WF; Hartmann A; Stoehr R Hum Pathol; 2006 Feb; 37(2):143-51. PubMed ID: 16426913 [TBL] [Abstract][Full Text] [Related]